Pharma BD Deal Intelligence
John Shulman, founder of Juggernaut Capital: "This merger will enable Petros to dramatically accelerate the commercial relaunch of Stendra and build a pipeline…
Petros President and CCO Fady Boctor: "With this merger, Petros will now have the opportunity to advance the commercial distribution of Stendra in the ED space…
signed to create awareness among patients and its partners.
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
Neurotrope and Metuchen Pharmaceuticals completed a reverse merger on December 1, 2020, forming Petros Pharmaceuticals, a publicly traded men's health company built around the commercial relaunch of the FDA-approved erectile dysfunction therapy Stendra. The transaction followed the failure of Neurotrope's lead Alzheimer's program and was accompanied by a $21.9 million private offering. Concurrent with the merger, Neurotrope spun off its neuroscience business as an independent company renamed Synaptogenix.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Metuchen Pharmaceuticals / Neurotrope Inc (this deal) | 2020 | $20M | 35 |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Servier / Agios Pharmaceuticals (oncology) | 2020 | $2.0B | 91 |
| Servier Pharmaceuticals LLC / Agios Pharmaceuticals Inc. | 2020 | $2.0B | 91 |
| Novo Nordisk A/S / Emisphere Technologies | 2020 | $1.4B | 90 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
← Browse all deals · How we score deals
More: 2020 deals